A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 13 Jan 2025
At a glance
- Drugs WVT 078 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 09 Jan 2025 Status changed from active, no longer recruiting to discontinued ,The decision was made for business reasons and was not based on any safety or tolerability concerns
- 14 Mar 2024 Planned End Date changed from 16 Sep 2024 to 2 Dec 2024.
- 14 Mar 2024 Planned primary completion date changed from 16 Sep 2024 to 29 Nov 2024.